ASXC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ASXC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asensus Surgical's yield on cost for the quarter that ended in Dec. 2023 was 0.00.
The historical rank and industry rank for Asensus Surgical's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Medical Devices subindustry, Asensus Surgical's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Asensus Surgical's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Asensus Surgical's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Asensus Surgical is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Asensus Surgical (AMEX:ASXC) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Asensus Surgical's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Starling William N Jr | director | 2300 BUCKSKIN ROAD, POCATELLO ID 83201 |
Andrea Biffi | director | C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060 |
Elizabeth Kwo | director | C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
David Bruce Milne | director | ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108 |
Kevin J Hobert | director | 343 STATE STREET, ROCHESTER NY 14650 |
Fernando Anthony C. J. | officer: Chief Technology Officer | 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560 |
Rampertab Shameze | officer: EVP, Chief Financial Officer | C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108 |
Brett Farabaugh | officer: Interim CFO | 108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709 |
Joseph P Slattery | officer: EVP and CFO | C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560 |
Eric A Smith | officer: Chief Commercial Officer | 7 CALEB CIRCLE, SAN ANTONIO TX 78258 |
Todd Pope | director, officer: President and CEO | C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713 |
Willam N Kelley | director | MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889 |
Pfenniger Richard C Jr | director | 4400 BISCAYNE BLVD., MIAMI FL 33137 |
Sofar, S.p.a | 10 percent owner | VIA FIRENZE 40, TREZZANO ROSA L6 20060 |
Andrew N Schiff | director, 10 percent owner | PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
From GuruFocus
By PRNewswire PRNewswire • 01-11-2021
By PRNewswire PRNewswire • 03-19-2019
By GF Value GF Value • 04-01-2021
By GuruFocusNews GuruFocusNews • 06-28-2022
By PRNewswire PRNewswire • 01-05-2021
By PRNewswire PRNewswire • 07-28-2021
By PRNewswire PRNewswire • 05-27-2021
By GuruFocusNews GuruFocusNews • 07-08-2022
By GF Value • 06-22-2021
By Barry Cohen Barry Cohen • 12-23-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.